Agios gains FDA priority review for Pyrukynd label expansion
Seeking Alpha ·
Shares of Agios Pharmaceuticals ( AGIO ) traded higher in the premarket on Tuesday after the U.S. FDA granted priority review for its marketing application seeking a label expansion for its lead product, Pyrukynd, in sickle cell disease.
DYAX Investor Sentiment
Bullish (Long) 68% · Bearish (Short) 32%
439 participants
Related News
- Neo Performance Materials offers exposure to the rare-earth magnet supply chain
- Cloudflare upgraded at ScotiaBank on AI traffic opportunity
- Rivian shares slide as EV maker to raise capital through stock offering
- SpaceX Insider Lockups Start Expiring in July. Here Is What That Means for the Stock.
- Cognizant expands AI partnership with Google Cloud; targets 200K Gemini users
- Photonic Inc. Names Orlagh Neary Chief Marketing Officer and Briony Shipman Vice President of Global Government Affairs